REGENERON PHARMACEUTICALS, INC.

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Cash flows from operating activities:
Adjustments to reconcile net income to net cash provided by operating activities:
Net Income From Continuing Operations $4.3b $4.0b $4.4b $4.5b
Net Income (Loss) Attributable to Parent $895.5m $1.2b $2.4b $2.1b $3.5b $8.1b $4.3b $4.0b $4.4b $4.5b
Depreciation, Depletion and Amortization $104.7m $145.5m $148.2m $210.3m $235.9m $286.2m $341.4m $421.0m $482.9m $543.7m
Depreciation $104.7m $142.2m $148.2m $210.3m $235.9m $286.2m $341.4m $421.0m $482.9m $543.7m
Amortization of Intangible Assets $92.2m $128.9m $178.8m
Amortization Cash Flow $37.6m $92.2m $128.9m
Amortization Of Intangibles $37.6m $92.2m $128.9m
Depreciation Amortization Depletion $341.4m $421.0m $482.9m $543.7m
Deferred Income Tax Expense (Benefit) ($360.1m) $319.0m ($140.0m) ($130.6m) $75.6m ($147.1m) ($746.4m) ($837.8m) ($757.3m) ($785.4m)
Deferred Income Tax ($746.4m) ($837.8m) ($757.3m) ($785.4m)
Deferred Tax ($746.4m) ($837.8m) ($757.3m) ($785.4m)
Share-based Payment Arrangement, Noncash Expense $559.9m $507.3m $427.4m $464.3m $432.0m $601.7m $725.0m $885.0m $982.8m $993.7m
Payment, Tax Withholding, Share-based Payment Arrangement $143.2m $301.7m $187.2m $188.0m $680.8m $1.0b $445.7m $700.6m $1.0b $532.1m
Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount $29.0m
Income Tax Expense (Benefit) $434.3m $880.0m $109.1m $313.3m $297.2m $1.3b $520.4m $245.7m $367.3m $725.8m
Interest Expense Nonoperating $55.2m $43.8m
Other Nonoperating Income (Expense) $6.3m $24.0m $47.3m $249.5m $290.7m $436.3m $179.3m $225.2m $844.4m $1.7b
Changes in operating assets and liabilities:
Additional Financial Items
Increase (Decrease) in Accounts Receivable $143.8m $362.7m $268.9m $473.1m $1.4b $1.9b ($707.8m) $338.8m $554.0m ($498.1m)
Increase (Decrease) in Inventories $149.8m $314.2m $387.9m $335.5m $529.4m $494.3m $696.5m $271.7m $619.7m $275.3m
Equity Securities, FV-NI, Gain (Loss) $955.6m
Equity Securities, FV-NI, Realized Gain (Loss) $966.2m
Equity Securities, FV-NI, Unrealized Gain (Loss) ($41.9m) $118.3m $196.0m $386.1m ($39.8m) ($237.8m) $117.7m ($10.6m)
Inventory Write-down $14.0m $73.8m $39.2m $457.1m $258.7m $102.3m $126.3m $172.9m
Nonoperating Income (Expense) ($926k) ($1.1m) $19.1m $219.3m $233.8m $379.0m $119.9m $152.2m $789.2m $1.7b
Payments for Repurchase of Warrants $643.4m $0 $0
Beginning Cash Position $2.9b $3.1b $2.7b $2.5b
Cash Flow From Continuing Financing Activities ($1.0b) ($1.8b) ($2.2b) ($3.7b)
Cash Flow From Continuing Investing Activities ($3.8b) ($3.2b) ($2.5b) ($629.1m)
Change In Account Payable ($138.4m) $598.6m $735.1m $736.8m
Change In Inventory ($696.5m) ($271.7m) ($619.7m) ($275.3m)
Change In Other Working Capital $32.4m $37.9m $227.8m ($51.7m)
Change In Payable ($138.4m) $598.6m $735.1m $736.8m
Change In Payables And Accrued Expense ($138.4m) $598.6m $735.1m $736.8m
Change In Prepaid Assets ($148.6m) ($120.1m) ($407.5m) ($375.3m)
Change In Receivables $707.8m ($338.8m) ($554.0m) $498.1m
Change In Working Capital ($243.3m) ($94.1m) ($618.3m) $532.6m
Changes In Account Receivables $707.8m ($338.8m) ($554.0m) $498.1m
Changes In Cash $221.3m ($381.2m) ($248.1m) $634.4m
End Cash Position $3.1b $2.7b $2.5b $3.1b
Financing Cash Flow ($1.0b) ($1.8b) ($2.2b) ($3.7b)
Free Cash Flow $3.4b $3.7b $3.5b $3.8b
Gain Loss On Investment Securities $36.8m $266.4m ($118.3m) ($946.1m)
Investing Cash Flow ($3.8b) ($3.2b) ($2.5b) ($629.1m)
Issuance Of Capital Stock $1.5b $1.1b $1.5b $635.9m
Net Business Purchase And Sale ($230.3m) ($54.9m) ($16.5m) ($3.3m)
Net Intangibles Purchase And Sale ($1.0b) ($207.8m) ($125.7m) ($315.3m)
Net PPE Purchase And Sale $0 $0 $20.1m $0
Operating Gains Losses $36.8m $266.4m ($118.3m) ($946.1m)
Other Non Cash Items $563.0m ($100k) $36.1m $135.5m
Purchase Of Business ($230.3m) ($54.9m) ($16.5m) ($3.3m)
Purchase Of Intangibles ($1.0b) ($207.8m) ($125.7m) ($315.3m)
Repurchase Of Capital Stock ($2.5b) ($2.9b) ($3.6b) ($4.0b)
Sale Of PPE $0 $0 $20.1m $0
Stock Based Compensation $725.0m $885.0m $982.8m $993.7m
Other Operating Income (Expense), Net $280.4m $45.6m $89.9m $2.1m ($53.4m) $10.0m
Net Cash Provided by (Used in) Operating Activities $1.5b $1.3b $2.2b $2.4b $2.6b $7.1b $5.0b $4.6b $4.4b $5.0b
Cash flows from investing activities:
Capital Expenditure ($1.6b) ($926.4m) ($881.6m) ($1.2b)
Capital Expenditure Reported $511.9m $272.6m $383.1m $429.6m $614.6m $551.9m ($590.1m) ($718.6m) ($755.9m) ($898.4m)
Payments to Acquire Businesses, Net of Cash Acquired $54.9m $16.5m $3.3m
Net Investment Purchase And Sale ($1.9b) ($2.2b) ($1.6b) $587.9m
Purchase Of Investment ($7.5b) ($11.6b) ($16.6b) ($11.0b)
Sale Of Investment $5.6b $9.4b $15.0b $11.5b
Payments for (Proceeds from) Other Investing Activities $10.0m $0 $0
Net Cash Provided by (Used in) Investing Activities ($1.0b) ($1.0b) ($1.5b) ($2.0b) ($70.6m) ($5.4b) ($3.8b) ($3.2b) ($2.5b) ($629.1m)
Cash flows from financing activities:
Proceeds from Issuance of Long-term Debt $2.0b $0 $0
Issuance Of Debt $0 $0
Long Term Debt Issuance $0 $0
Net Issuance Payments Of Debt $0 $0
Net Long Term Debt Issuance $0 $0
Long Term Debt Payments $0 $0
Repayment Of Debt $0 $0
Proceeds from Issuance of Common Stock $126.7m $240.2m $114.5m $211.8m $2.6b $1.7b $1.5b $1.1b $1.5b $635.9m
Common Stock Issuance $1.5b $1.1b $1.5b $635.9m
Net Common Stock Issuance ($1.0b) ($1.8b) ($2.2b) ($3.3b)
Payments for Repurchase of Common Stock $143.2m $301.7m $4.4m $275.9m $5.8b $1.6b $2.1b $2.2b $2.6b $3.4b
Common Stock Payments ($2.5b) ($2.9b) ($3.6b) ($4.0b)
Dividends paid $0 $0 $370.3m
Cash Dividends Paid $0 $0 ($370.3m)
Common Stock Dividend Paid $0 $0 ($370.3m)
Proceeds from (Payments for) Other Financing Activities ($33.4m) ($10.3m)
Net Other Financing Charges ($33.4m) ($10.3m)
Net Cash Provided by (Used in) Financing Activities ($700.4m) ($24.4m) ($77.1m) ($252.1m) ($2.0b) ($1.0b) ($1.0b) ($1.8b) ($2.2b) ($3.7b)
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $0 $0 ($400k) ($700k) $300k
Effect Of Exchange Rate Changes $0 ($400k) ($700k) $300k
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $150.1m $577.0m $690.8m $221.3m ($381.6m) ($248.8m) $634.7m
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $1.5b $1.6b $2.2b $2.9b $3.1b $2.7b $2.5b $3.1b
Supplemental disclosure of cash flow information:
Change In Cash Supplemental As Reported $221.3m ($381.6m) ($248.8m) $634.7m
Interest Paid, Excluding Capitalized Interest, Operating Activities $5.5m $18.7m $22.3m $25.0m $23.2m $55.8m $53.7m $73.1m $52.6m $41.6m
Income Taxes Paid, Net $481.4m $754.8m $205.6m $342.3m $188.1m $1.2b $1.5b $870.3m $743.0m $1.3b

Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.